Results 261 to 270 of about 327,168 (302)

Expression of biologically active human interferon alpha 2 in Aloe vera

Transgenic Research, 2012
Methods necessary for the successful transformation and regeneration of Aloe vera were developed and used to express the human protein, interferon alpha 2 (IFNα2). IFNα2 is a secreted cytokine that plays a vital role in regulating the cellular response to viral infection.
William, Lowther, Kevin, Lorick, Susan D, Lawrence, Wen-Shuz, Yeow   +3 more
openaire   +2 more sources

Congenital juvenile chronic myelogenous leukemia: Therapeutic trial with interferon alpha‐2

Medical and Pediatric Oncology, 1993
AbstractA newborn with congenital juvenile chronic myelogenous leukemia (JCML) is described. The diagnosis was suggested by the characteristic clinical and hematologic presentation, and was confirmed by the results of in‐vitro cultures of the hematopoietic progenitors, which showed excessive proliferation of monocytic colonies, with and without the ...
A, Hazani, Y, Barak, M, Berant, A, Bar-Maor   +3 more
openaire   +2 more sources

[Alpha 2 -interferon therapy in metastasizing malignant melanoma].

Deutsche medizinische Wochenschrift (1946), 1987
Low doses of recombinant alpha 2-interferon were administered to 20 patients with stage III malignant melanoma. Dosage was 2.5 million IU intramuscularly daily in the first four weeks, then 2.5 million IU twice a week. The treatment was well tolerated, but there was no definitely demonstrable therapeutic effect.
M, Landthaler, C, Geyer, U, Papendick, O, Braun-Falco   +3 more
openaire   +1 more source

[Immunogenicity of recombinant interferon alpha-2 in therapy].

Bratislavske lekarske listy, 1999
Recombinant human (r)IFN-alpha 2 is successfully used in treatment of haematopoietic malignancies, lymphomas and viral hepatitis B and C as well. One of undesired side-effects of rIFN-alpha 2 is its immunogenicity which could decrease therapeutic potential of the drug. Formation of antibodies against rIFN-alpha 2 in man represents a complex process, in
H, Liptakova, P, Kontsek
openaire   +1 more source

Interferon alpha 2-b therapy of HCV and NonBNonC chronic hepatitis

1992
Twenty-four patients with HCV and NonBNonC chronic hepatitis--4 with HIV coinfection--were treated with r-IFN alpha for at least six months. In this period 62.5% of patients show a normalization of ALT but not a sustained remission. Non-responders have histologically more severe and long-lasting chronic hepatitis.
M, Gargiulo, P, Tarquini, L, Di Ottavio, E, Lattanzi, A, De Nigris-Urbani   +4 more
openaire   +2 more sources

Interferon alpha 2

Reactions Weekly, 1994
openaire   +2 more sources

Effect of intralesional alpha 2-interferon on actinic keratoses.

Archives of dermatology, 1986
The effect of intralesional alpha 2-interferon (IFN) on actinic keratoses was examined in this two-part study. In phase I, 11 of 12 lesions cleared following nine injections of IFN (5 X 10(5) IU per dose) compared with none of 12 keratoses injected with placebo. Smaller doses of IFN (1 X 10(5) IU and 1 X 10(4) IU per injection) produced clearing of 42%
L, Edwards, N, Levine, M, Weidner, M, Piepkorn, K, Smiles   +4 more
openaire   +1 more source

Interferon alpha 2

Reactions Weekly, 1991
openaire   +2 more sources

Neuroendocrine effects of interferon alpha 2-a in healthy human subjects.

Journal of biological regulators and homeostatic agents, 1990
The acute effects of interferon alpha-2a (3 x 10 IU im) on catecholamine and immunoreactive beta endorphin plasma levels, cortisol serum levels and lymphocyte beta 2-adrenoceptor density were evaluated in ten healthy volunteers. Interferon induced a significant increase in plasma norepinephrine; there was an increased norepinephrine standing response ...
PENDE, ALDO, N. R. MUSSO, C. VERGASSOLA, F. PUPPO, A. IOVERNO, D. CRISCUOLO, F. INDIVERI, G. LOTTI   +7 more
openaire   +2 more sources

[Antibodies against alpha-2 and gamma-interferons affect the course of juvenile respiratory papillomatosis in children treated with alpha-2 interferon preparations].

Vestnik otorinolaringologii, 1997
1-year or longer treatment of juvenile respiratory papillomatosis (JRP) with alpha-2 interferons (A21) leads to emergence of antibodies to A21 in 54.3% of the patients. The greatest percentage of the antibody positives (94.4%) was found among JRP patients treated with intramuscular recombinant human A21 (reaferon).
V D, Kol'tsov, E K, Onufrieva, R Kh, Nurmukhamedov, V V, Malinovskaya, F I, Yershov   +4 more
openaire   +1 more source